Pancreatitis cases linked to weight loss jabs
GLP-1 drugs like Ozempic and Mounjaro are under review in the UK after a spike in adverse reactions.
Advertisement
The Health Products Regulatory Authority (HPRA) said the number of Irish cases is very low, but people should consult their doctor if they are concerned.
HSE national clinical lead for obesity, Professor Donal O'Shea, said it is important people use these drugs under medical supervision.
Prof O'Shea said: "The main side effects are gastrointestinal and that's around nausea, vomiting, constipation, but they can cause unsteadiness and dizziness.
"And I've certainly seen people coming into hospital having had falls on these treatements, and again the advice is not to take these unless they are prescribed by a healthcare professional."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BreakingNews.ie
an hour ago
- BreakingNews.ie
Hospital overcrowding: Over 500 patients without a bed in Irish hospitals
501 people are being treated on trolleys in Irish hospitals on Tuesday, according to the Irish Nurses and Midwives Organisation (INMO). 331 patients are waiting in the emergency department, while 170 are in wards elsewhere in hospitals. Advertisement The hospital with the highest number of people without a bed is University Hospital Limerick with 111 patients on trolleys. 38 people are in the emergency department, with 73 people elsewhere in the hospital. 50 people are without a bed at University Hospital Galway, with 36 patients in the emergency department. At Sligo University Hospital, there are 45 people without a bed, with 24 patients in the emergency department.
Reuters
2 hours ago
- Reuters
Viking's oral pill reduces up to 12.2% weight but shares slump on higher patient exits
Aug 19 (Reuters) - Viking Therapeutics (VKTX.O), opens new tab said on Tuesday its experimental weight-loss pill helped people with obesity lose up to 12.2% of their body weight over 13 weeks in a keenly watched study. Yet, shares of the company slumped nearly 35% in premarket trading after data showed that more patients who received Viking's drug stopped taking the treatment, compared to those who received placebo in the mid-stage study. Oral drugs are expected to take a significant share of the projected $150 billion weight-loss market, driven by their ease of use compared with injections such as Novo Nordisk's ( opens new tab Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound. Viking's experimental oral pill is in a tight race with rival treatments being developed by the deeper-pocketed Novo and Lilly. Earlier this month, Eli Lilly said its experimental daily pill, orforglipron, showed a 12.4% weight loss in patients in a late-stage study over 72 weeks. In a separate trial, Novo's oral semaglutide has shown a weight loss of 15% over 68 weeks. Both the oral drugs are expected to be launched next year. Ahead of Viking's data, analysts expected weight loss in the range of 10% to 15% on average for the pill, known as VK2735. It had shown an 8.2% average weight-loss in a small early-stage trial. About 20% of those who received the drug discontinued due to an adverse effect, compared to 13% on placebo in the 280-patient study. The most common reasons for treatment discontinuation were gastrointestinal side effects, the company said. Like Lilly's Zepbound, Viking's drug also targets hormones known as GLP-1 and GIP that play a critical role in regulating the body's metabolism. Viking is testing both the oral and under-the-skin injection forms of the drug in overweight patients who have who at least one weight-related comorbidity.
Reuters
3 hours ago
- Reuters
The race to launch first weight-loss pill
August 19 - Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's (LLY.N), opens new tab Zepbound and Novo Nordisk's ( opens new tab Wegovy. The GLP-1 drugs sold by both companies are weekly injections, although several drugmakers are racing to develop an oral medicine or pill that might prove to be as effective as the injectables. Pills are easier to manufacture and could also avoid some of the supply issues that were initially seen with Novo and Lilly's drugs. Here are some companies developing oral obesity drugs in the hopes of making their mark in a lucrative market: Orforglipron, the company's once-daily oral non-peptide GLP-1 agonist, helped patients shed 12.4% of body weight over 72 weeks at the highest dose in a late-stage trial. Lilly plans to file for regulatory approval by the end of 2025 and is preparing for global submissions and manufacturing scale-up. Oral semaglutide, a pill version of the company's injectable GLP-1 active ingredient, demonstrated about 15% weight loss in a late-stage trial. The drug is currently under regulatory review, with a U.S. FDA decision expected in late 2025. Novo is also exploring next-generation oral combinations. Structure Therapeutics is developing GSBR-1290, a non-peptide oral GLP-1 agonist. Last year, the drug helped reduce weight by 6.2% on average at the end of 12 weeks in a mid-stage study. It is expected to report results from another mid-stage trial in the fourth quarter. The company, in partnership with Hansoh Pharma, is preparing to test HS-10535, an oral small-molecule GLP-1 agonist, in early-stage trials. The drug is currently being tested in lab studies. AstraZeneca and Eccogene are advancing ECC5004, a once-daily GLP-1 receptor agonist pill. Early stage trial showed a promising weight-loss signal and a favorable safety profile, with mid stage trials planned under AstraZeneca's lead. Roche, following its acquisition of Carmot Therapeutics, is working on CT-966, an oral GLP-1 agonist. CT-966 resulted in a placebo-adjusted average weight loss of 6.1% within four weeks in obese patients without diabetes in an early-stage trial last year. The company is developing an oral formulation of VK2735, which targets both GLP-1 and GIP hormones that regulate the body's metabolism. In a mid-stage study of 280 overweight adults with at least one obesity-related comorbidity, the pill achieved up to 12.2% mean weight loss over 13 weeks, compared with placebo. Pfizer was developing danuglipron, initially as a twice-daily oral GLP-1 agonist, but scrapped development after data from a mid-stage trial showed poor tolerability. A once-daily extended-release version was later tested in about 1,400 patients but liver safety concerns remained, dampening the company's plans to enter the obesity drug market.
